Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Review uri icon

Overview

abstract

  • Malignant pleural mesothelioma (MPM) is an aggressive, primary pleural malignancy with poor prognosis, hypothesized to originate from a chronic inflammatory state within the pleura. Similar to what has been observed in other solid tumors (melanoma, ovarian and colorectal cancer), clinical and pre-clinical MPM investigations have correlated anti-tumor immune responses with improved survival. As such, a better understanding of the complex MPM tumor microenvironment is imperative in strategizing successful immunotherapies. Herein, we review the immune responses vital to the development and progression of MPM, as well as assess the role of immunomodulatory therapies, highlighting recent pre-clinical and clinical immunotherapy investigations.

publication date

  • September 13, 2011

Research

keywords

  • Immunotherapy
  • Mesothelioma
  • Pleural Neoplasms

Identity

PubMed Central ID

  • PMC3268654

Scopus Document Identifier

  • 82355175864

Digital Object Identifier (DOI)

  • 10.1007/s00262-011-1103-6

PubMed ID

  • 21913025

Additional Document Info

volume

  • 60

issue

  • 11